Advertisement
U.S. Markets closed

  • S&P 500

    5,626.02
    +30.26 (+0.54%)
    ?

  • Dow 30

    41,393.78
    +297.01 (+0.72%)
    ?

  • Nasdaq

    17,683.98
    +114.30 (+0.65%)
    ?

  • Russell 2000

    2,182.49
    +53.06 (+2.49%)
    ?

  • Crude Oil

    69.24
    +0.27 (+0.39%)
    ?

  • Gold

    2,606.20
    +25.60 (+0.99%)
    ?

  • Silver

    31.07
    +0.96 (+3.18%)
    ?

  • EUR/USD

    1.1079
    +0.0002 (+0.0222%)
    ?

  • 10-Yr Bond

    3.6500
    -0.0300 (-0.82%)
    ?

  • Vix

    16.56
    -0.51 (-2.99%)
    ?

  • GBP/USD

    1.3125
    +0.0000 (+0.0013%)
    ?

  • USD/JPY

    140.7640
    -1.0730 (-0.7565%)
    ?

  • BTC-USD

    59,775.90
    +1,966.54 (+3.40%)
    ?

  • CMC Crypto 200

    1,308.28
    0.00 (0.00%)
    ?

  • FTSE 100

    8,273.09
    +32.12 (+0.39%)
    ?

  • Nikkei 225

    36,581.76
    -251.51 (-0.68%)
    ?

JPMorgan initiates coverage on GLP-1 entrant Viking Therapeutics

1
In this article:

JPMorgan initiates coverage on Viking Therapeutics (VKTX) with an Overweight rating and price target of $80 per share. Viking Therapeutics stock has jumped 10% on Wednesday, currently hovering above $60.

Market Domination hosts Julie Hyman and Josh Lipton report on the analyst note, also noting Novo Nordisk's (NVO) and Roche's (ROG.SW, RHHBY) own plans for experimental obesity pills.

In an August installment of Good Buy or Goodbye, RSE Ventures Co-Founder and CEO Matt Higgins told Yahoo Finance why he believes Viking Therapeutics will become a new leader in the GLP-1 weight-loss drug space.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Luke Carberry Mogan.

Advertisement